-
公开(公告)号：US11702419B2
公开(公告)日：2023-07-18
申请号：US17201878
申请日：2021-03-15
发明人： Yuya Oguro , Shigemitsu Matsumoto , Takeshi Wakabayashi , Norihito Tokunaga , Taku Kamei , Mitsuhiro Ito , Satoshi Mikami , Masaki Seto , Shinji Morimoto , Shinji Nakamura , Sachie Takashima , Masataka Murakami , Masaki Daini , Makoto Kamata , Minoru Nakamura , Yasufumi Wada , Hiroyuki Kakei , Kazuaki Takami , Taisuke Tawaraishi , Jumpei Aida , Kouichi Iwanaga , Satoshi Yamamoto
IPC分类号： C07D487/04 , A61K9/20 , A61K9/48 , C07D471/04 , A61P25/00
CPC分类号： C07D487/04 , A61K9/2095 , A61K9/4833 , A61P25/00 , C07D471/04
摘要： The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I):
wherein each symbol is as described in the description, or a salt thereof.-
公开(公告)号：US11274101B2
公开(公告)日：2022-03-15
申请号：US16651840
申请日：2018-09-27
发明人： Makoto Kamata , Hideyuki Sugiyama , Minoru Nakamura , Masataka Murakami , Shuhei Ikeda , Tomohiro Okawa , Hidekazu Tokuhara
IPC分类号： C07D487/10 , A61P25/28 , A61K9/20 , A61K9/48
摘要： The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号：US10457670B2
公开(公告)日：2019-10-29
申请号：US15830634
申请日：2017-12-04
发明人： Masami Yamada , Shinkichi Suzuki , Takahiro Sugimoto , Minoru Nakamura , Hiroki Sakamoto , Makoto Kamata
IPC分类号： C07D405/14 , C07D405/04 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , A61K31/145 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D471/04 , C07D403/10 , A61K31/13 , A61K31/045
摘要： The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US20180346452A1
公开(公告)日：2018-12-06
申请号：US15830634
申请日：2017-12-04
发明人： Masami YAMADA , Shinkichi Suzuki , Takahiro Sugimoto , Minoru Nakamura , Hiroki Sakamoto , Makoto Kamata
IPC分类号： C07D405/14 , C07D405/04 , A61K31/045 , C07D403/10 , C07D403/04 , C07D401/14 , C07D401/10 , C07D401/06 , C07D209/46 , A61K31/55 , A61K31/445 , A61K31/4439 , A61K31/4406 , A61K31/4155 , A61K31/4035 , A61K31/325 , A61K31/13 , C07D471/04
摘要： The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US09775827B2
公开(公告)日：2017-10-03
申请号：US15488002
申请日：2017-04-14
发明人： Masami Yamada , Shinkichi Suzuki , Takahiro Sugimoto , Minoru Nakamura , Hiroki Sakamoto , Makoto Kamata
IPC分类号： C07D209/46 , C07D403/10 , C07D405/14 , C07D403/04 , C07D401/10 , C07D401/14 , A61K31/4035 , A61K31/445 , A61K31/55 , A61K31/325 , A61K31/4155 , A61K31/4439
CPC分类号： C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
摘要： The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US11834409B2
公开(公告)日：2023-12-05
申请号：US18087233
申请日：2022-12-22
发明人： Shuhei Ikeda , Makoto Kamata , Yuya Oguro , Masataka Murakami , Minoru Nakamura , Fumie Yamaguchi , Takafumi Yukawa
IPC分类号： C07D207/263 , A61P25/18 , C07D401/06
CPC分类号： C07D207/263 , A61P25/18 , C07D401/06
摘要： A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
-
公开(公告)号：US11459325B2
公开(公告)日：2022-10-04
申请号：US16961476
申请日：2019-01-30
发明人： Yuta Tanaka , Tomohiro Ohashi , Zenichi Ikeda , Yuta Tanaka , Florian Pünner , Takeshi Yamamoto , Keiko Kakegawa , Fumiaki Kikuchi , Nao Morishita , Takahito Kasahara , Masaki Seto , Minoru Nakamura , Kazuaki Takami , Masataka Murakami , Masaki Daini , Satoshi Mikami , Minoru Sasaki
IPC分类号： C07D471/04 , C07D487/04 , C07D491/048 , C07D495/04 , C07D519/00 , A61P25/28
摘要： The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.-
公开(公告)号：US10208046B2
公开(公告)日：2019-02-19
申请号：US15311025
申请日：2015-05-15
发明人： Takahiro Sugimoto , Kenichiro Shimokawa , Takuto Kojima , Hiroki Sakamoto , Ikuo Fujimori , Minoru Nakamura , Masami Yamada , Masataka Murakami , Makoto Kamata , Shinkichi Suzuki
IPC分类号： A61K31/437 , C07D487/04 , A61K31/444 , A61K31/4545 , A61K31/501 , A61K31/519 , C07D471/04
摘要： The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH═ or —N═, or a salt thereof.
-
公开(公告)号：US10087150B2
公开(公告)日：2018-10-02
申请号：US15799379
申请日：2017-10-31
发明人： Takahiro Sugimoto , Shinkichi Suzuki , Hiroki Sakamoto , Masami Yamada , Minoru Nakamura , Makoto Kamata , Kenichiro Shimokawa , Takuto Kojima
IPC分类号： C07D265/22 , C07D413/14 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D471/04 , C07D491/107 , C07F7/02
摘要： The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
公开(公告)号：US09878989B2
公开(公告)日：2018-01-30
申请号：US15190642
申请日：2016-06-23
发明人： Takahiro Sugimoto , Shinkichi Suzuki , Hiroki Sakamoto , Masami Yamada , Minoru Nakamura , Makoto Kamata , Kenichiro Shimokawa , Masataka Murakami , Jinichi Yonemori , Takuto Kojima
IPC分类号： C07D471/04 , C07D413/14 , C07D413/06 , C07D413/10 , C07D417/06 , C07D491/107 , C07D265/22 , C07F7/02 , C07D413/04
CPC分类号： C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
摘要： The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.038 秒)
